Bank of New York Mellon’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-210
| Closed | -$17K | – | 4378 |
|
|
2020
Q4 | $17K | Hold |
210
| – | – | ﹤0.01% | 4197 |
|
|
2020
Q3 | $13K | Hold |
210
| – | – | ﹤0.01% | 4099 |
|
|
2020
Q2 | $19K | Sell |
210
-4,201
| -95% | -$444K | ﹤0.01% | 4057 |
|
|
2020
Q1 | $494K | Sell |
4,411
-100
| -2% | -$19.7K | ﹤0.01% | 3377 |
|
|
2019
Q4 | $1.1M | Buy |
4,511
+492
| +12% | +$124K | ﹤0.01% | 3193 |
|
|
2019
Q3 | $1.38M | Buy |
4,019
+1
| +0% | +$544 | ﹤0.01% | 2964 |
|
|
2019
Q2 | $3.7M | Sell |
4,018
-2,631
| -40% | -$3.23M | ﹤0.01% | 2484 |
|
|
2019
Q1 | $10.6M | Buy |
6,649
+2,629
| +65% | +$4.74M | ﹤0.01% | 1941 |
|
|
2018
Q4 | $7.51M | Sell |
4,020
-145
| -3% | -$316K | ﹤0.01% | 2069 |
|
|
2018
Q3 | $9.82M | Sell |
4,165
-239
| -5% | -$740K | ﹤0.01% | 2035 |
|
|
2018
Q2 | $15.2M | Sell |
4,404
-119
| -3% | -$364K | ﹤0.01% | 1772 |
|
|
2018
Q1 | $12.8M | Sell |
4,523
-229
| -5% | -$686K | ﹤0.01% | 1858 |
|
|
2017
Q4 | $12.2M | Buy |
4,752
+117
| +3% | +$333K | ﹤0.01% | 1893 |
|
|
2017
Q3 | $13.2M | Buy |
4,635
+104
| +2% | +$274K | ﹤0.01% | 1840 |
|
|
2017
Q2 | $10.7M | Sell |
4,531
-321
| -7% | -$636K | ﹤0.01% | 1926 |
|
|
2017
Q1 | $12.2M | Buy |
4,852
+274
| +6% | +$789K | ﹤0.01% | 1847 |
|
|
2016
Q4 | $10.3M | Buy |
4,578
+209
| +5% | +$497K | ﹤0.01% | 1941 |
|
|
2016
Q3 | $10.9M | Sell |
4,369
-12
| -0.3% | -$35.8K | ﹤0.01% | 1834 |
|
|
2016
Q2 | $13.4M | Sell |
4,381
-159
| -4% | -$517K | ﹤0.01% | 1675 |
|
|
2016
Q1 | $14.4M | Sell |
4,540
-1,294
| -22% | -$5.37M | ﹤0.01% | 1612 |
|
|
2015
Q4 | $29.9M | Sell |
5,834
-10
| -0.2% | -$43.7K | 0.01% | 1123 |
|
|
2015
Q3 | $18.6M | Buy |
5,844
+364
| +7% | +$1.41M | 0.01% | 1460 |
|
|
2015
Q2 | $21.9M | Buy |
5,480
+197
| +4% | +$761K | 0.01% | 1423 |
|
|
2015
Q1 | $21.1M | Buy |
5,283
+1,814
| +52% | +$8.31M | 0.01% | 1454 |
|
|
2014
Q4 | $17M | Sell |
3,469
-480
| -12% | -$2.06M | ﹤0.01% | 1586 |
|
|
2014
Q3 | $16.1M | Sell |
3,949
-92
| -2% | -$345K | ﹤0.01% | 1598 |
|
|
2014
Q2 | $16.3M | Sell |
4,041
-204
| -5% | -$832K | ﹤0.01% | 1620 |
|
|
2014
Q1 | $19.3M | Buy |
4,245
+43
| +1% | +$174K | 0.01% | 1482 |
|
|
2013
Q4 | $14.7M | Buy |
4,202
+513
| +14% | +$2M | ﹤0.01% | 1655 |
|
|
2013
Q3 | $15.1M | Buy |
3,689
+248
| +7% | +$1.07M | ﹤0.01% | 1578 |
|
|
2013
Q2 | $13.6M | Buy |
+3,441
| New | +$14.2M | ﹤0.01% | 1612 |
|
Other funds holding ACOR
CCA
Bank of New York Mellon's ACOR Position: Q1 2021 in Review
Bank of New York Mellon sold out of Acorda Therapeutics (ACOR) in Q1 2021, closing a stake of 210 shares — an estimated $17K sold.
Bank of New York Mellon first reported a position in ACOR in Q2 2013 and held it in 31 quarters. The position peaked at $29.9M in Q4 2015. 32 funds tracked by Wall St. Rank hold ACOR as of Q1 2021.
- Bank of New York Mellon reported no remaining Acorda Therapeutics position as of Q1 2021 after selling out during the quarter.
- Bank of New York Mellon sold 210 Acorda Therapeutics shares in Q1 2021, an estimated $17K.
- Bank of New York Mellon first reported a position in Acorda Therapeutics in Q2 2013 and held it in 31 quarters.
- Bank of New York Mellon's Acorda Therapeutics position peaked at $29.9M in Q4 2015.
- 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2021.
Based on Bank of New York Mellon's 13F filing for Q1 2021, filed 13 May 2021.